|
1
|
Dang CV: Cancer metabolism: The known,
unknowns. Biochim Biophys Acta Rev Cancer. 1870:12018.
|
|
2
|
Martinez-Reyes I and Chandel NS: Cancer
metabolism: Looking forward. Nat Rev Cancer. 21:669–680. 2021.
|
|
3
|
Trefts E and Shaw RJ: AMPK: Restoring
metabolic homeostasis over space and time. Mol Cell. 81:3677–3690.
2021.
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.
|
|
5
|
Zecchin A, Kalucka J, Dubois C and
Carmeliet P: How endothelial cells adapt their metabolism to form
vessels in tumors. Front Immunol. 8:17502017.
|
|
6
|
Losman JA, Koivunen P and Kaelin WG Jr:
2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer.
20:710–726. 2020.
|
|
7
|
Liao C and Zhang Q: Understanding the
oxygen-sensing pathway and its therapeutic implications in
diseases. Am J Pathol. 190:1584–1595. 2020.
|
|
8
|
Semenza GL: The Genomics and genetics of
oxygen homeostasis. Annu Rev Genomics Hum Genet. 21:183–204.
2020.
|
|
9
|
Koivunen P and Kietzmann T:
Hypoxia-inducible factor prolyl 4-hydroxylases and metabolism.
Trends Mol Med. 24:1021–1035. 2018.
|
|
10
|
Wong BW, Kuchnio A, Bruning U and
Carmeliet P: Emerging novel functions of the oxygen-sensing prolyl
hydroxylase domain enzymes. Trends Biochem Sci. 38:3–11. 2013.
|
|
11
|
Maxwell PH and Eckardt KU: HIF prolyl
hydroxylase inhibitors for the treatment of renal anaemia and
beyond. Nat Rev Nephrol. 12:157–168. 2016.
|
|
12
|
Singh L, Aldosary S, Saeedan AS, Ansari MN
and Kaithwas G: Prolyl hydroxylase 2: A promising target to inhibit
hypoxia-induced cellular metabolism in cancer cells. Drug Discov
Today. 23:1873–1882. 2018.
|
|
13
|
Kato H, Inoue T, Asanoma K, Nishimura C,
Matsuda T and Wake N: Induction of human endometrial cancer cell
senescence through modulation of HIF-1alpha activity by EGLN1. Int
J Cancer. 118:1144–1153. 2006.
|
|
14
|
Kaelin WG Jr: The VHL tumor suppressor
gene: Insights into oxygen sensing and cancer. Trans Am Clin
Climatol Assoc. 128:298–307. 2017.
|
|
15
|
Chen F, Chen J, Yang L, Liu J, Zhang X,
Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al: Extracellular
vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated
macrophages regulates aerobic glycolysis of breast cancer cells.
Nat Cell Biol. 21:498–510. 2019.
|
|
16
|
Sadiku P, Willson JA, Dickinson RS, Murphy
F, Harris AJ, Lewis A, Sammut D, Mirchandani AS, Ryan E, Watts ER,
et al: Prolyl hydroxylase 2 inactivation enhances glycogen storage
and promotes excessive neutrophilic responses. J Clin Invest.
127:3407–3420. 2017.
|
|
17
|
Guentsch A, Beneke A, Swain L, Farhat K,
Nagarajan S, Wielockx B, Raithatha K, Dudek J, Rehling P, Zieseniss
A, et al: PHD2 is a regulator for glycolytic reprogramming in
macrophages. Mol Cell Biol. 37:e00236–16. 2016.
|
|
18
|
Xiang L, Gilkes DM, Hu H, Takano N, Luo W,
Lu H, Bullen JW, Samanta D, Liang H and Semenza GL:
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear
localization to induce the breast cancer stem cell phenotype.
Oncotarget. 5:12509–12527. 2014.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
20
|
Farooq SM, Hou Y, Li H, O'Meara M, Wang Y,
Li C and Wang JM: Disruption of GPR35 exacerbates dextran sulfate
sodium-induced colitis in mice. Dig Dis Sci. 63:2910–2922.
2018.
|
|
21
|
Wang S, Wu Y, Hou Y, Guan X, Castelvetere
MP, Oblak JJ, Banerjee S, Filtz TM, Sarkar FH, Chen X, et al: CXCR2
macromolecular complex in pancreatic cancer: A potential
therapeutic target in tumor growth. Transl Oncol. 6:216–225.
2013.
|
|
22
|
Ruifrok AC and Johnston DA: Quantification
of histochemical staining by color deconvolution. Anal Quant Cytol
Histol. 23:291–299. 2001.
|
|
23
|
Xie G, Zheng L, Ou J, Huang H, He J, Li J,
Pan F and Liang H: Low expression of prolyl hydroxylase 2 is
associated with tumor grade and poor prognosis in patients with
colorectal cancer. Exp Biol Med (Maywood). 237:860–866. 2012.
|
|
24
|
Zhou L, Wang Y, Zhou M, Zhang Y, Wang P,
Li X, Yang J, Wang H and Ding Z: HOXA9 inhibits HIF-1α-mediated
glycolysis through interacting with CRIP2 to repress cutaneous
squamous cell carcinoma development. Nat Commun. 9:14802018.
|
|
25
|
Dupuy F, Tabariès S, Andrzejewski S, Dong
Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, et al:
PDK1-dependent metabolic reprogramming dictates metastatic
potential in breast cancer. Cell Metab. 22:577–589. 2015.
|
|
26
|
Denko NC: Hypoxia, HIF1 and glucose
metabolism in the solid tumour. Nat Rev Cancer. 8:705–713.
2008.
|
|
27
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl
hydroxylation. Science. 292:468–472. 2001.
|
|
28
|
Vidimar V, Licona C, Cerón-Camacho R,
Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R,
Jung AC, et al: A redox ruthenium compound directly targets PHD2
and inhibits the HIF1 pathway to reduce tumor angiogenesis
independently of p53. Cancer Lett. 440-441:145–155. 2019.
|
|
29
|
Meneses AM and Wielockx B: PHD2: From
hypoxia regulation to disease progression. Hypoxia (Auckl).
4:53–67. 2016.
|
|
30
|
Cummins EP, Berra E, Comerford KM,
Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE,
Moynagh P, Pouyssegur J and Taylor CT: Prolyl hydroxylase-1
negatively regulates IkappaB kinase-beta, giving insight into
hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA.
103:18154–18159. 2006.
|
|
31
|
Chan DA, Kawahara TLA, Sutphin PD, Chang
HY, Chi JT and Giaccia AJ: Tumor vasculature is regulated by
PHD2-mediated angiogenesis and bone marrow-derived cell
recruitment. Cancer Cell. 15:527–538. 2009.
|
|
32
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer.
12:862013.
|
|
33
|
Birbach A, Gold P, Binder BR, Hofer E, de
Martin R and Schmid JA: Signaling molecules of the NF-kappa B
pathway shuttle constitutively between cytoplasm and nucleus. J
Biol Chem. 277:10842–10851. 2002.
|
|
34
|
Rückert F, Grützmann R and Pilarsky C:
Feedback within the inter-cellular communication and tumorigenesis
in carcinomas. PLoS One. 7:e367192012.
|
|
35
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015.
|
|
36
|
Obacz J, Pastorekova S, Vojtesek B and
Hrstka R: Cross-talk between HIF and p53 as mediators of molecular
responses to physiological and genotoxic stresses. Mol Cancer.
12:932013.
|
|
37
|
Johnson RF and Perkins ND: Nuclear
factor-κB, p53, and mitochondria: Regulation of cellular metabolism
and the Warburg effect. Trends Biochem Sci. 37:317–324. 2012.
|
|
38
|
Wilde L, Roche M, Domingo-Vidal M, Tanson
K, Philp N, Curry J and Martinez-Outschoorn U: Metabolic coupling
and the reverse Warburg effect in cancer: Implications for novel
biomarker and anticancer agent development. Semin Oncol.
44:198–203. 2017.
|
|
39
|
Wang X, Liu R, Qu X, Yu H, Chu H, Zhang Y,
Zhu W, Wu X, Gao H, Tao B, et al: α-Ketoglutarate-activated NF-κB
signaling promotes compensatory glucose uptake and brain tumor
development. Mol Cell. 76:148–162.e7. 2019.
|
|
40
|
Ishak Gabra MB, Yang Y, Lowman XH, Reid
MA, Tran TQ and Kong M: IKKβ activates p53 to promote cancer cell
adaptation to glutamine deprivation. Oncogenesis. 7:932018.
|
|
41
|
Ruf M, Pitzen T, Meyer C and Drumm J:
Atlantoaxial rotatory dislocation: Delayed diagnose will result in
more invasive treatment options. J Neurol Surg A Cent Eur
Neurosurg. 82:1–8. 2021.
|
|
42
|
Taniguchi K and Karin M: NF-κB,
inflammation, immunity and cancer: Coming of age. Nat Rev Immunol.
18:309–324. 2018.
|
|
43
|
Gaete D, Rodriguez D, Watts D, Sormendi S,
Chavakis T and Wielockx B: HIF-prolyl hydroxylase domain proteins
(PHDs) in cancer-potential targets for anti-tumor therapy? Cancers
(Basel). 13:9882021.
|
|
44
|
Chen T, Zhou Q, Tang H, Bozkanat M, Yuan
JX, Raj JU and Zhou G: miR-17/20 controls prolyl hydroxylase 2
(PHD2)/hypoxia-inducible factor 1 (HIF1) to regulate pulmonary
artery smooth muscle cell proliferation. J Am Heart Assoc.
5:e0045102016.
|
|
45
|
Lee G, Won HS, Lee YM, Choi JW, Oh TI,
Jang JH, Choi DK, Lim BO, Kim YJ, Park JW, et al: Oxidative
dimerization of PHD2 is responsible for its inactivation and
contributes to metabolic reprogramming via HIF-1alpha activation.
Sci Rep. 6:189282016.
|
|
46
|
Li J, Yuan W, Jiang S, Ye W, Yang H,
Shapiro IM and Risbud MV: Prolyl-4-hydroxylase domain protein 2
controls NF-κB/p65 transactivation and enhances the catabolic
effects of inflammatory cytokines on cells of the nucleus pulposus.
J Biol Chem. 290:7195–7207. 2015.
|
|
47
|
Wang L, Niu Z, Wang X, Li Z, Liu Y, Luo F
and Yan X: PHD2 exerts anti-cancer and anti-inflammatory effects in
colon cancer xenografts mice via attenuating NF-κB activity. Life
Sci. 242:1171672020.
|
|
48
|
Lee DC, Sohn HA, Park ZY, Oh S, Kang YK,
Lee KM, Kang M, Jang YJ, Yang SJ and Hong YK: A lactate-induced
response to hypoxia. Cell. 161:595–609. 2015.
|
|
49
|
Romero-Ruiz A, Bautista L, Navarro V,
Heras-Garvín A, March-Díaz R, Castellano A, Gómez-Díaz R, Castro
MJ, Berra E, López-Barneo J and Pascual A: Prolyl
hydroxylase-dependent modulation of eukaryotic elongation factor 2
activity and protein translation under acute hypoxia. J Biol Chem.
287:9651–9658. 2012.
|
|
50
|
Wang X, Xie J and Proud CG: Eukaryotic
elongation factor 2 kinase (eEF2K) in cancer. Cancers.
9:1622017.
|
|
51
|
Xue J, Li X, Jiao S, Wei Y, Wu G and Fang
J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer
cells and inhibits IKKbeta independent of hydroxylase activity.
Gastroenterology. 138:606–615. 2010.
|
|
52
|
Lind DS, Hochwald SN, Malaty J, Rekkas S,
Hebig P, Mishra G, Moldawer LL, Copeland EM III and Mackay S:
Nuclear factor-kappa B is upregulated in colorectal cancer.
Surgery. 130:363–369. 2001.
|
|
53
|
Wang Z, Sheng C, Kan G, Yao C, Geng R and
Chen S: RNAi screening identifies that TEX10 promotes the
proliferation of colorectal cancer cells by increasing NF-κB
activation. Adv Sci (Weinh). 7:20005932020.
|
|
54
|
Goka ET, Chaturvedi P, Lopez DTM, Garza A
and Lippman ME: RAC1b overexpression confers resistance to
chemotherapy treatment in colorectal cancer. Mol Cancer Ther.
18:957–968. 2019.
|
|
55
|
Gyamfi J, Kim J and Choi J: Cancer as a
metabolic disorder. Int J Mol Sci. 23:11552022.
|
|
56
|
Ge T, Gu X, Jia R, Ge S, Chai P, Zhuang A
and Fan X: Crosstalk between metabolic reprogramming and
epigenetics in cancer: Updates on mechanisms and therapeutic
opportunities. Cancer Commun (Lond). 42:1049–1082. 2022.
|
